These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A Synthetic SARS-CoV-2-Derived T-Cell and B-Cell Peptide Cocktail Elicits Full Protection against Lethal Omicron BA.1 Infection in H11-K18-hACE2 Mice. Song Y; Hu H; Xiao K; Huang X; Guo H; Shi Y; Zhao J; Zhu S; Ji T; Xia B; Jiang J; Cao L; Zhang Y; Zhang Y; Xu W Microbiol Spectr; 2023 Mar; 11(2):e0419422. PubMed ID: 36912685 [TBL] [Abstract][Full Text] [Related]
8. A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts. Schultz MD; Suschak JJ; Botta D; Silva-Sanchez A; King RG; Detchemendy TW; Meshram CD; Foote JB; Zhou F; Tipper JL; Zhang J; Harrod KS; Leal SM; Randall TD; Roberts MS; Georges B; Lund FE Hum Vaccin Immunother; 2022 Nov; 18(6):2127292. PubMed ID: 36194255 [TBL] [Abstract][Full Text] [Related]
9. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection. van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP Front Immunol; 2021; 12():781280. PubMed ID: 34987509 [TBL] [Abstract][Full Text] [Related]
11. Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate. Patel DR; Field CJ; Septer KM; Sim DG; Jones MJ; Heinly TA; Vanderford TH; McGraw EA; Sutton TC J Virol; 2021 Jun; 95(13):e0223220. PubMed ID: 33827954 [TBL] [Abstract][Full Text] [Related]
12. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. Zhou R; Wang P; Wong YC; Xu H; Lau SY; Liu L; Mok BW; Peng Q; Liu N; Woo KF; Deng S; Tam RC; Huang H; Zhang AJ; Zhou D; Zhou B; Chan CY; Du Z; Yang D; Au KK; Yuen KY; Chen H; Chen Z EBioMedicine; 2022 Jan; 75():103762. PubMed ID: 34942445 [TBL] [Abstract][Full Text] [Related]
13. Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine. An D; Li K; Rowe DK; Diaz MCH; Griffin EF; Beavis AC; Johnson SK; Padykula I; Jones CA; Briggs K; Li G; Lin Y; Huang J; Mousa J; Brindley M; Sakamoto K; Meyerholz DK; McCray PB; Tompkins SM; He B Sci Adv; 2021 Jul; 7(27):. PubMed ID: 34215591 [TBL] [Abstract][Full Text] [Related]
15. Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. Sheward DJ; Mandolesi M; Urgard E; Kim C; Hanke L; Perez Vidakovics L; Pankow A; Smith NL; Castro Dopico X; McInerney GM; Coquet JM; Karlsson Hedestam GB; Murrell B Cell Rep Med; 2021 Nov; 2(11):100450. PubMed ID: 34723224 [TBL] [Abstract][Full Text] [Related]
16. Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2. Jearanaiwitayakul T; Seesen M; Chawengkirttikul R; Limthongkul J; Apichirapokey S; Sapsutthipas S; Phumiamorn S; Sunintaboon P; Ubol S Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358183 [TBL] [Abstract][Full Text] [Related]
17. Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. Xu K; An Y; Li Q; Huang W; Han Y; Zheng T; Fang F; Liu H; Liu C; Gao P; Xu S; Liu X; Zhang R; Zhao X; Liu WJ; Bi Y; Wang Y; Zhou D; Wang Q; Hou W; Xia Q; Gao GF; Dai L Emerg Microbes Infect; 2021 Dec; 10(1):1574-1588. PubMed ID: 34289779 [TBL] [Abstract][Full Text] [Related]
18. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Liu R; Americo JL; Cotter CA; Earl PL; Erez N; Peng C; Moss B Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33688035 [TBL] [Abstract][Full Text] [Related]
19. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896 [TBL] [Abstract][Full Text] [Related]
20. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity. Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D Front Immunol; 2021; 12():748103. PubMed ID: 34867974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]